Valproic acid-associated hyperammonemia is a common adverse effect that may occur within therapeutic range of VPA. Further studies are required to determine the benefit of routine ammonia level monitoring and to guide the management of VPA-associated hyperammonemia.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2023) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: